| Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria |
|
International Journal of Molecular Sciences |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society of Blood and Marrow Transplantation |
|
Haematologica |
Aplastic Anemia |
| The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
|
Frontiers in Oncology |
Aplastic Anemia |
| Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
|
The Oncologist |
Myelodysplastic Syndromes (MDS) |
| Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
|
The Oncologist |
Myelodysplastic Syndromes (MDS) |
| Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Newly revised 2023 MDS response criteria |
|
Blood |
Myelodysplastic Syndromes (MDS) |
